Advertisement

The National Methadone Maintenance Treatment Program

  • Xiaobin CaoEmail author
  • Chunqing Lin
  • Changhe Wang
  • Zunyou Wu
Chapter

Abstract

Drug use reemerged in China after the 1978 introduction of sweeping economic change initiated by the “Opening Up and Reform” policy, and the high-risk behavior of drug users was the major driver of China’s early HIV epidemic. To combat both the growing drug use and HIV epidemics, China’s National Methadone Maintenance Treatment (MMT) Program was piloted in 2004 and scaled up starting in 2006. By the end of 2015, the program encompassed 785 full-service clinics, 29 mobile vans, and 325 satellite sites nationwide that were providing MMT services to more than 170,000 regular clients who were former heroin injectors. China’s National MMT Program had become the largest opioid substitution therapy program in the world. This important harm reduction program has successfully reduced illicit drug use, HIV incidence, mortality, and criminal activity, as well as improved quality of life. However, there are still a wide range of challenges and gaps remaining, and further work to strengthen this program will be necessary for HIV to be eliminated in this important key population.

Notes

Acknowledgments

The authors would like to thank Willa Dong and Jennifer M. McGoogan for providing editorial assistance.

References

  1. Ausubel DP. The Dole-Nyswander treatment of heroin addiction. JAMA. 1966;195(11):949–50.  https://doi.org/10.1001/jama.1966.03100110117032.CrossRefPubMedGoogle Scholar
  2. Brugal M, Domingo-Salvany A, Puig R, Barrio G, García de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction. 2005;100(7):981–9.  https://doi.org/10.1111/j.1360-0443.2005.01089.x.CrossRefPubMedGoogle Scholar
  3. Cao XB, Wu ZY, Li L, Pang L, Rou K, Wang C, et al. Mortality among methadone maintenance clients in China: a six-year cohort study. PLoS One. 2013;8(12):e82476.  https://doi.org/10.1371/journal.pone.0082476.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cao X, Wu Z, Rou K, Li L, Lin C, Wang C, Luo W, et al. Retention and its predictors among methadone maintenance treatment clients in China: a six-year cohort study. Drug Alcohol Depend. 2014;145:87–93.  https://doi.org/10.1016/j.drugalcdep.2014.09.776.CrossRefPubMedGoogle Scholar
  5. Chinese Center for Disease Control and Prevention. National sentinel surveillance report of HIV infection, 2004. Beijing: Chinese Center for Disease Control and Prevention; 2004.Google Scholar
  6. Corsi KF, Booth RE. HIV sex risk behaviors among heterosexual methamphetamine users: literature review from 2000 to present. Curr Drug Abuse Rev. 2008;1(3):292–6.  https://doi.org/10.2174/1874473710801030292.CrossRefPubMedGoogle Scholar
  7. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect. 2006;82(Suppl 3):iii56–63.  https://doi.org/10.1136/sti.2005.019273.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Fang YX, Wang YB, Shi J, Liu ZM, Lu L. Recent trends in drug abuse in China. Acta Pharmacol Sin. 2006;27:140–4.  https://doi.org/10.1111/j.1745-7254.2006.00270.x.CrossRefPubMedGoogle Scholar
  9. Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286(14):1724–31.  https://doi.org/10.1001/jama.286.14.1724.CrossRefPubMedGoogle Scholar
  10. Hulse GK, English DR, Milne E, Holman CD. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94(2):221–9.  https://doi.org/10.1046/j.1360-0443.1999.9422216.x.CrossRefPubMedGoogle Scholar
  11. Jia Z, Liu Z, Chu P, McGoogan JM, Cong M, Shi J, et al. Tracking the evolution of drug abuse in China, 2003–10: a retrospective, self-controlled study. Addiction. 2015;110(Suppl 1):4–10.  https://doi.org/10.1111/add.12769.CrossRefPubMedGoogle Scholar
  12. Joe Laidler KA. The rise of club drugs in a heroin society: the case of Hong Kong. Subst Use Misuse. 2005;40(9–10):1257–78.  https://doi.org/10.1081/JA-200066788.CrossRefPubMedGoogle Scholar
  13. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5–6):347–64.PubMedGoogle Scholar
  14. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of poly-substance using injection drug users in Vancouver. Drug Alcohol Depend. 2005;80(3):329–35.  https://doi.org/10.1016/j.drugalcdep.2005.05.002.CrossRefPubMedGoogle Scholar
  15. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. Methadone maintenance treatment modalities in relation to incidence of HIV: results of the Amsterdam cohort study. AIDS. 1999;13(13):1711–6.CrossRefGoogle Scholar
  16. Li J, Ha TH, Zhang C, Liu H. The Chinese government’s response to drug use and HIV/AIDS: a review of policies and programs. Harm Reduct J. 2010;7:4.  https://doi.org/10.1186/1477-7517-7-4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Li L, Wu Z, Cao X, Zhang L. Provider-client interaction in methadone treatment clinics in China. J Drug Issues 2012;42(2).  https://doi.org/10.1177/0022042612446593.CrossRefGoogle Scholar
  18. Li J, Wang C, McGoogan JM, Rou K, Bulterys M, Wu Z. Human resource development and capacity-building during China’s rapid scale-up of methadone maintenance treatment services. Bull World Health Organ. 2013;91(2):130–5.  https://doi.org/10.2471/BLT.12.108951.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lin C, Wu Z, Rou K, Pang L, Cao X, Shoptaw S, et al. Challenges in providing services in methadone maintenance therapy clinics in China: service providers’ perceptions. Int J Drug Policy. 2010;21(3):173–8.  https://doi.org/10.1016/j.drugpo.2009.09.002.CrossRefGoogle Scholar
  20. Lin C, Detels R. A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China. Drug Alcohol Depend. 2011;117(1):45–9.  https://doi.org/10.1016/j.drugalcdep.2011.01.004.CrossRefGoogle Scholar
  21. Lin C, Li L, Cao X. Client acceptability for integrating antiretroviral therapy in methadone maintenance therapy clinics in Sichuan, China. Subst Use Misuse. 2017;52(1):119–26.  https://doi.org/10.1080/10826084.2016.1222622.CrossRefPubMedGoogle Scholar
  22. Liu H, Grusky O, Zhu Y, Li X. Do drug users who frequently receive detoxification treatment change their risky drug use practices and sexual behavior? Drug Alcohol Depend. 2006;84(1):114–21.  https://doi.org/10.1016/j.drugalcdep.2006.01.004.CrossRefPubMedGoogle Scholar
  23. Liu E, Liang T, Shen L, Zhong H, Wang B, Wu Z, et al. Correlates of methadone client retention: a prospective cohort study in Guizhou province, China. Int J Drug Policy. 2009;20(4):304–8.  https://doi.org/10.1016/j.drugpo.2008.09.004.CrossRefPubMedGoogle Scholar
  24. Liu Y, Liang J, Zhao C, Zhou W. Looking for a solution for drug addiction in China: exploring the challenges and opportunities in the way of China’s new Drug Control Law. Int J Drug Policy. 2010;21(3):149–54.  https://doi.org/10.1016/j.drugpo.2009.10.002.CrossRefPubMedGoogle Scholar
  25. Liu E, Rou K, McGoogan JM, Pang L, Cao X, Wang C, et al. Factors associated with mortality of HIV positive clients receiving methadone maintenance treatment in China. J Infect Dis. 2013;208(3):442–53.  https://doi.org/10.1093/infdis/jit163.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Lu L, Wang X. Drug addiction in China. Ann N Y Acad Sci. 2008;1141:304–17.  https://doi.org/10.1196/annals.1441.025.CrossRefPubMedGoogle Scholar
  27. Lu L, Fang Y, Wang X. Drug abuse in China: past, present and future. Cell Mol Neurobiol. 2008;28(4):479–90.  https://doi.org/10.1007/s10571-007-9225-2.CrossRefPubMedGoogle Scholar
  28. Ma Y, Li Z, Zhang K. HIV was first discovered among injection drug users in China. Chin J Epidemiol. 1990;11:184–5.Google Scholar
  29. Mao Y, Wu Z, Poundstone K, Wang C, Qin Q, Ma Y, et al. Development of a unified web-based national HIV/AIDS information system in China. Int J Epidemiol. 2010;39(Suppl 2):ii79–89.  https://doi.org/10.1093/ije/dyq213.CrossRefPubMedPubMedCentralGoogle Scholar
  30. McCowan C, Kidd B, Fahey T. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ. 2009;338:b2225.  https://doi.org/10.1136/bmj.b2225.CrossRefPubMedPubMedCentralGoogle Scholar
  31. McCoy CB, McCoy HV, Lai S, Yu Z, Wang X, Meng J. Reawakening the dragon: changing patterns of opiate use in Asia, with particular emphasis on China’s Yunnan province. Subst Use Misuse. 2001;36(1–2):49–69.CrossRefGoogle Scholar
  32. Meng J, Burris S. The role of the Chinese police in methadone maintenance therapy: a literature review. Int J Drug Policy. 2013;24(6):e25–34.  https://doi.org/10.1016/j.drugpo.2013.03.010.CrossRefPubMedGoogle Scholar
  33. Ministry of Health, Ministry of Public Security, State Food and Drug Administration. Implementation protocol of the community-based methadone maintenance treatment program for opiate addicts in China. Beijing: Ministry of Health, Ministry of Public Security, and State Food and Drug Administration, People’s Republic of China; 2006.Google Scholar
  34. Morgan O, Johnson H, Rooney C, Seagroatt V, Griffiths C. Changes to the daily pattern of methadone-related deaths in England and Wales, 1993–2003. J Public Health (Oxf). 2006;28(4):318–23.  https://doi.org/10.1093/pubmed/fdl059.CrossRefGoogle Scholar
  35. National Health and Family Planning Commission. 2015 China AIDS response progress report. Beijing: National Health and Family Planning Commission. http://www.commuhealtibet.org/wp-content/uploads/2016/11/CHN_narrative_report_2015.pdf. Accessed 27 Sep 2018.
  36. National Narcotic Control Commission. Annual report on drug control in China. Beijing: National Narcotics Control Commission, People’s Republic of China; 2005.Google Scholar
  37. National Narcotics Control Commission. Annual report on drug control in China. Beijing: National Narcotics Control Commission, People’s Republic of China; 2013.Google Scholar
  38. National Narcotics Control Commission. Annual report on drug control in China. Beijing: National Narcotics Control Commission, People’s Republic of China; 2015.Google Scholar
  39. Pang L, Hao Y, Mi G, Wang C, Luo W, Rou K, et al. Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS. 2007;21(Suppl 8):S103–7.  https://doi.org/10.1097/01.aids.0000304704.71917.64.CrossRefGoogle Scholar
  40. Peles E, Kreek MJ, Kellogg S, Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. J Addict Dis. 2006;25(1):43–50.  https://doi.org/10.1300/J069v25n01_07.CrossRefPubMedGoogle Scholar
  41. Shao Y, Chen Z, Wang B, Zeng Y, Zhao SD, Zhang ZR. Isolation of viruses from HIV infected individuals in Yunnan. Chin J Epidemiol. 1991;12:129.Google Scholar
  42. Shi J, Zhao LY, Epstein DH, Zhang XL, Lu L. Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers. Pharmacol Biochem Behav. 2007;87(1):141–5.  https://doi.org/10.1016/j.pbb.2007.04.010.CrossRefPubMedGoogle Scholar
  43. Standing Committee of the National People’s Congress of China. Drug control law. Beijing: Standing Committee of the National People’s Congress of China, People’s Republic of China; 2008.Google Scholar
  44. State Council. China’s action plan for reducing and preventing the spread of HIV/AIDS (2001–2005). Beijing: State Council, People’s Republic China; 2001.Google Scholar
  45. State Council. Regulations on AIDS prevention and treatment. Beijing: State Council, People’s Republic of China; 2006a.Google Scholar
  46. State Council. Action plan on HIV/AIDS prevention and containment (2006–2010). Beijing: State Council, People’s Republic of China; 2006b.Google Scholar
  47. State Council AIDS Working Committee Office and the United Nations Theme Group on HIV/AIDS in China. A joint assessment of HIV/AIDS prevention, treatment and care in China. Beijing: State Council AIDS Working Committee Office and the United Nations Theme Group on HIV/AIDS in China; 2004.Google Scholar
  48. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281(11):1000–5.  https://doi.org/10.1001/jama.281.11.1000.CrossRefPubMedGoogle Scholar
  49. Sullivan SG, Wu Z. Rapid scale up of harm reduction in China. Int J Drug Policy. 2007;18(2):118–28.  https://doi.org/10.1016/j.drugpo.2006.11.014.CrossRefGoogle Scholar
  50. Sullivan SG, Wu Z, Cao X, Liu E, Detels R. Continued drug use during methadone treatment in China: a retrospective analysis of 19,026 service users. J Subst Abus Treat. 2014;47(1):86–92.  https://doi.org/10.1016/j.jsat.2013.12.004.CrossRefGoogle Scholar
  51. Sullivan SG, Wu Z, Rou K, Pang L, Luo W, Wang C, et al. Who uses methadone services in China? Monitoring the world’s largest methadone programme. Addiction. 2015;110(Suppl 1):29–39.  https://doi.org/10.1111/add.12781.CrossRefPubMedGoogle Scholar
  52. Sun X, Wang N, Li D, Zheng X, Qu S, Wang L, et al. The development of HIV/AIDS surveillance in China. AIDS. 2007;21(Suppl 8):S33–8.  https://doi.org/10.1097/01.aids.0000304694.54884.06.CrossRefGoogle Scholar
  53. Sun X, Lu F, Wu Z, Poundstone K, Zeng G, Xu P, et al. Evolution of information-driven HIV/AIDS policies in China. Int J Epidemiol. 2010;39(Suppl 2):ii4–13.  https://doi.org/10.1093/ije/dyq217.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Sun HM, Li XY, Chow EP, Li T, Xian Y, Lu YH, et al. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open. 2015;5(1):e005997.  https://doi.org/10.1136/bmjopen-2014-005997.CrossRefPubMedPubMedCentralGoogle Scholar
  55. United Nations Office on Drugs and Crime. World drug report 2012. Vienna: United Nations Office on Drugs and Crime; 2012.CrossRefGoogle Scholar
  56. Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis. 2004;38(6):890–4.  https://doi.org/10.1086/381975.CrossRefPubMedGoogle Scholar
  57. Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C. Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission. Am J Psychiatry. 2007;164(1):157–60.  https://doi.org/10.1176/ajp.2007.164.1.157.CrossRefPubMedGoogle Scholar
  58. Wang BX, Zhang L, Wang YJ, Yan JW, Wan YN, Peng WJ, et al. Epidemiology of syphilis infection among drug users at methadone maintenance treatment clinics in China: systemic review and meta-analysis. Int J STD AIDS. 2014;25(8):550–8.  https://doi.org/10.1177/0956462413515444.CrossRefGoogle Scholar
  59. Wang L, Guo W, Li D, Ding Z, McGoogan JM, Wang N. HIV epidemic among drug users in China: 1995–2011. Addiction. 2015;110(Suppl 1):20–8.  https://doi.org/10.1111/add.12779.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Wang C, Shi CX, Rou K, Zhao Y, Cao X, Luo W, et al. Baseline HCV antibody prevalence and risk factors among drug users in China’s National Methadone Maintenance Treatment Program. PLoS One. 2016;11(2):e0147922.  https://doi.org/10.1371/journal.pone.0147922.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353(9148):221–6.  https://doi.org/10.1016/S0140-6736(98)05356-2.CrossRefPubMedGoogle Scholar
  62. World Health Organization China Office. Reducing harm, preventing HIV, saving lives: China’s vast methadone maintenance treatment program marks successes even as it addresses key challenges ahead. Beijing: World Health Organization China Office; 2014. http://www.wpro.who.int/china/mediacentre/releases/2014/2014112702/en/. Accessed 27 Sep 2018.
  63. World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Beijing: World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS, 2004. http://www.who.int/hiv/pub/idu/position_paper_substitution_opioid/en/. Accessed 19 Sept 2018.
  64. Wu Z, Pisani E. Fulfilling a promise: universal care. In: Wu Z, editor. HIV/AIDS in China—beyond the numbers. Singapore: People’s Medical Publishing House; 2017. p. 78–99.CrossRefGoogle Scholar
  65. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China’s response to HIV/AIDS. Lancet. 2007;369(9562):679–90.  https://doi.org/10.1016/S0140-6736(07)60315-8.CrossRefGoogle Scholar
  66. Yin W, Hao Y, Sun X, Gong X, Li F, Li J. Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol. 2010;39(Suppl 2):ii29–37.  https://doi.org/10.1093/ije/dyq210.CrossRefPubMedPubMedCentralGoogle Scholar
  67. Yin W, Pang L, Cao X, McGoogan JM, Liu M, Zhang C, et al. Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China. Addiction. 2015;110(Suppl 1):51–60.  https://doi.org/10.1111/add.12780.CrossRefPubMedGoogle Scholar
  68. Zhang H. An analysis of the group characteristics of new-type drugs abuse in Dehong prefecture. J Yunnan Police Officer Acad. 2006;4:16–8.Google Scholar
  69. Zhang L, Chow EP, Zhuang X, Liang Y, Wang Y, Tang C, et al. Methadone maintenance treatment participant retention and behavioral effectiveness in China: a systematic review and meta-analysis. PLoS One. 2013;8:e68906.  https://doi.org/10.1371/journal.pone.0068906.CrossRefPubMedPubMedCentralGoogle Scholar
  70. Zhao Y, Shi CX, McGoogan JM, Rou K, Zhang F, Wu Z. Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ. 2013;91(2):93–101.  https://doi.org/10.2471/BLT.12.108944.CrossRefPubMedPubMedCentralGoogle Scholar
  71. Zheng X, Tian C, Choi KH, Zhang J, Cheng H, Yang X, et al. Injecting drug use and HIV infection in southwest China. AIDS. 1994;8:1141–7.CrossRefGoogle Scholar
  72. Zhou Y, Zhuang G. Retention in methadone maintenance treatment in mainland China, 2004–2012: a literature review. Addict Behav. 2014;39(1):22–9.  https://doi.org/10.1016/j.addbeh.2013.09.001.CrossRefPubMedGoogle Scholar
  73. Zhou Y, Wu Z, McGoogan JM, Luo W, Zhang B, Wu L, et al. Mortality and associated factors among methadone maintenance treatment clients in Yunnan, China: an eleven-year cohort study. J Addict Med. 2019 (under review).Google Scholar
  74. Zhuang X, Liang Y, Chow EP, Wang Y, Wilson DP, Zhang L. HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis. BMC Infect Dis. 2012;12:130.  https://doi.org/10.1186/1471-2334-12-130.CrossRefPubMedPubMedCentralGoogle Scholar
  75. Zou X, Ling L, Zhang L. Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study. BMJ Open. 2015;5(8):e008162.  https://doi.org/10.1136/bmjopen-2015-008162.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Xiaobin Cao
    • 1
    Email author
  • Chunqing Lin
    • 2
  • Changhe Wang
    • 1
  • Zunyou Wu
    • 1
  1. 1.NCAIDSChina CDCBeijingChina
  2. 2.UCLALos AngelesUSA

Personalised recommendations